FDA概述细胞/基因疗法CMC灵活性 可能对诺华与辉瑞有利

环球市场播报
Jan 14

  美国食品药品监督管理局(FDA)详细说明了为加速细胞与基因治疗开发而定制的生产与控制让步措施,同时保持标准,这可能对诺华(NVS)和辉瑞(PFE)等开发商构成潜在利好。

海量资讯、精准解读,尽在新浪财经APP

责任编辑:张俊 SF065

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10